Hims & Hers Health (HIMS) Long-Term Debt Issuances (2019 - 2021)

Hims & Hers Health (HIMS) reported Long-Term Debt Issuances of $1.2 million for Q1 2021, up 1832.92% sequentially from $61720.0 in Q4 2019.

Hims & Hers Health (HIMS) Long-Term Debt Issuances (2019 - 2021) Analysis & Trends

Hims & Hers Health (HIMS) has 2 years of Long-Term Debt Issuances data on file, last reported at $1.2 million in Q1 2021.

For the quarter ending Q1 2021, Long-Term Debt Issuances changed N/A year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2021 stood at $1.2 million (changed N/A YoY), and the FY2025 full-year result was $970.0 million, changed N/A from the prior year.
Long-Term Debt Issuances grew to $1.2 million in Q1 2021, from $61720.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $1.2 million in Q1 2021 to a low of $61720.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Haleon	88.07 Bn	86.20 Bn	-	-
2	Teva Pharmaceutical Industries	35.75 Bn	32.01 Bn	1.97 Bn	-
3	Zoetis	31.84 Bn	29.90 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	27.18 Bn	23.12 Bn	4.39 Bn	3.64 Bn
5	United Therapeutics	23.09 Bn	20.93 Bn	648.10 Mn	-
6	RedHill Biopharma	21.32 Bn	21.32 Bn	-	-
7	Viatris	19.96 Bn	18.16 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.66 Bn	16.34 Bn	800.70 Mn	-
9	Elanco Animal Health	12.44 Bn	12.02 Bn	785.00 Mn	-
10	Hims & Hers Health	6.44 Bn	5.69 Bn	396.79 Mn	-

Download Data